BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
34
Data completeness
7/8 — Comprehensive
Priority Review
IMJUDO (tremelimumab) by AstraZeneca is ctla-4-directed antibody interactions [moa]. Approved for hepatocellular carcinoma, non-small cell lung cancer. First approved in 2022.
IMJUDO (tremelimumab) is a monoclonal antibody that blocks CTLA-4, an immune checkpoint, to enhance T-cell activation and anti-tumor immunity. It is approved for treatment across 25+ solid tumor indications including hepatocellular carcinoma, non-small cell lung cancer, urothelial cancer, pancreatic cancer, and melanoma. The drug works by removing immune suppression, enabling the body's immune system to recognize and attack cancer cells.
$2MPart D
PeakEarly-stage peak lifecycle with modest Medicare uptake ($2M, 65 claims in 2023) suggests significant growth runway and active brand-building opportunities.
Mechanism of Action
CTLA-4-directed Antibody Interactions
Pharmacologic Class:
CTLA-4-directed Blocking Antibody
Indications (2)
Worked on IMJUDO at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.